Senti Biosciences is trading 12% down at $0.85 today despite a lack of fresh company-specific news or regulatory filings to explain the move.
- The decline appears idiosyncratic, likely driven by low liquidity and recent volatility inherent in this micro-cap biotech name.
- Broader U.S. equity futures are trading modestly higher, suggesting the downward pressure is decoupled from general market sentiment.
- The move is attributed to general risk sensitivity rather than a specific fundamental catalyst or headline.